profit from every $100 of sales.
$0$100
Alzamend Neuro
$1.42+0.71% today
-40.3% in 1 year
1-year low $0.861-year high $2.44
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Alzamend Neuro sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$4.51 million of profit last year.
SalesProfit
Alzamend Neuro vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Alzamend Neuro | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Alzamend Neuro's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -12 | -15 | -10 | -4 | |
| -12 | -15 | -10 | -4 | |
| -12 | -15 | -10 | -5 | |
| -189.00 | -228.90 | -132.33 | -11.32 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 15 | 6 | 1 | 5 |
| Cash | 14 | 5 | 0 | 4 |
| Total debt | – | – | 0 | – |
| Total liabilities | 1 | 3 | 3 | 1 |
| 13 | 3 | -3 | 4 | |
| 0 | 0 | 0 | 0 | |
| -72.9% | -385.7% | – | -89.5% | |
| -92.6% | -488.5% | 383.5% | -113.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -7 | -9 | -8 | -7 | |
| 0 | – | 0 | 0 | |
| -7 | -9 | -8 | -7 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 4 | 4 | 1 | 0 |
Valuation
- –
- –
- –
- 1.8×
- –
- –
- –
- -100.2%
- -65.9%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -322.0%
- -95.2%
- -177.5%
- -174.2%
- -322.0%
- –
Growth
- –
- –
- +18.4%
- –
- +65.5%
Financial health
- -0.4×
- 0.00
- 0.0%
- -1,008.2×
- 1.99
- 1.99
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 871
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 11, 2026 | -0.58 | -0.53 | −9.4% |
| Dec 9, 2025 | -0.30 | -0.83 | +63.9% |
| Sep 10, 2025 | -1.28 | -3.69 | +65.3% |
| Mar 10, 2025 | -1.71 | -2.61 | +34.5% |
| Dec 11, 2024 | -3.60 | -21.42 | +83.2% |
| Sep 11, 2024 | -11.25 | -2.38 | −372.7% |
| Jul 30, 2024 | -13.35 | -2.75 | −385.5% |
| Mar 25, 2024 | -34.20 | -0.32 | −10,587.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
48No pass
Philip Fisher
35No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
34No pass
Questions about Alzamend Neuro
Is Alzamend Neuro a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Alzamend Neuro AI analysis
What does Alzamend Neuro do?
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. It is in Biotechnology.
Does Alzamend Neuro pay a dividend?
No. Alzamend Neuro does not pay a dividend at the moment.
Is Alzamend Neuro stock halal?
No. Alzamend Neuro does not pass our halal screen: its cash and confirmed interest-bearing investments are 58% of its market value, at or above the 33% limit. How we check
How has Alzamend Neuro stock done over the past year?
Down 40.3% over the past twelve months, to $1.42. It traded between $0.86 and $2.44 and is 41.8% below its high.
Who are Alzamend Neuro's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Alzamend Neuro's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.